Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2025 delivered strong operational and strategic outcomes through disciplined execution, improving gross profit and Adjusted EBITDAS margins over prior year

    80% confidence
  • Recapitalization Transaction significantly strengthened balance sheet and positioned organization to advance growth strategy

    80% confidence
  • Liquidity and cash flows from operations will be sufficient to meet short-term contractual obligations and maintain compliance with financial covenants through December 31, 2026

    80% confidence
  • Company remains committed to core values and customer-centric focus to deliver services safely, on time, and on budget, enabling growth strategy through industrial market diversification and geographic expansion

    80% confidence
  • TRIF reached 0.10, the best safety performance in company history

    80% confidence
  • Revenue decline from prior year due to persistent market uncertainty that weighed on customer spending

    80% confidence
  • New contract awards of $914.4 million provide solid foundation for 2026

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com